WO2022157493A1 - Méthode de traitement de troubles histiocytaires et lymphoprolifératifs associés à il-6 - Google Patents
Méthode de traitement de troubles histiocytaires et lymphoprolifératifs associés à il-6 Download PDFInfo
- Publication number
- WO2022157493A1 WO2022157493A1 PCT/GB2022/050151 GB2022050151W WO2022157493A1 WO 2022157493 A1 WO2022157493 A1 WO 2022157493A1 GB 2022050151 W GB2022050151 W GB 2022050151W WO 2022157493 A1 WO2022157493 A1 WO 2022157493A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- treatment
- per
- fragment
- week interval
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 208000030289 Lymphoproliferative disease Diseases 0.000 title claims description 34
- 238000011282 treatment Methods 0.000 claims abstract description 477
- 239000012634 fragment Substances 0.000 claims abstract description 185
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 163
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 162
- 208000032641 idiopathic multicentric Castleman disease Diseases 0.000 claims abstract description 123
- 238000011269 treatment regimen Methods 0.000 claims abstract description 88
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract description 60
- 102000052611 human IL6 Human genes 0.000 claims abstract description 60
- 239000005557 antagonist Substances 0.000 claims abstract description 39
- 230000019491 signal transduction Effects 0.000 claims abstract description 31
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 24
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 16
- 229960003323 siltuximab Drugs 0.000 claims description 220
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 112
- 102100032752 C-reactive protein Human genes 0.000 claims description 112
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 87
- 201000010099 disease Diseases 0.000 claims description 77
- 210000002966 serum Anatomy 0.000 claims description 72
- 208000015325 multicentric Castleman disease Diseases 0.000 claims description 40
- 238000001802 infusion Methods 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 230000008901 benefit Effects 0.000 claims description 23
- 206010061818 Disease progression Diseases 0.000 claims description 21
- 230000005750 disease progression Effects 0.000 claims description 21
- 238000001990 intravenous administration Methods 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 15
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 201000008298 histiocytosis Diseases 0.000 claims description 14
- 208000031314 Rosaï-Dorfman disease Diseases 0.000 claims description 12
- 208000006489 Sinus Histiocytosis Diseases 0.000 claims description 12
- 208000022417 sinus histiocytosis with massive lymphadenopathy Diseases 0.000 claims description 12
- 208000034578 Multiple myelomas Diseases 0.000 claims description 11
- 239000003246 corticosteroid Substances 0.000 claims description 11
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 9
- 229960003989 tocilizumab Drugs 0.000 claims description 8
- 230000003211 malignant effect Effects 0.000 claims description 7
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000012051 H syndrome Diseases 0.000 claims description 2
- 208000031287 Primary hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000012829 chemotherapy agent Substances 0.000 claims description 2
- 208000014681 genetic hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 2
- 208000014342 histiocytosis-lymphadenopathy plus syndrome Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000014673 secondary hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 description 155
- 230000004044 response Effects 0.000 description 101
- 208000024891 symptom Diseases 0.000 description 55
- 210000001165 lymph node Anatomy 0.000 description 46
- 238000002560 therapeutic procedure Methods 0.000 description 46
- 239000003814 drug Substances 0.000 description 45
- 210000004369 blood Anatomy 0.000 description 44
- 239000008280 blood Substances 0.000 description 44
- 229940079593 drug Drugs 0.000 description 41
- 238000004458 analytical method Methods 0.000 description 36
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 36
- 238000012216 screening Methods 0.000 description 27
- 238000003745 diagnosis Methods 0.000 description 26
- 230000001965 increasing effect Effects 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 230000035935 pregnancy Effects 0.000 description 22
- 239000000090 biomarker Substances 0.000 description 21
- 238000011156 evaluation Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 238000012544 monitoring process Methods 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 208000005024 Castleman disease Diseases 0.000 description 18
- 238000012552 review Methods 0.000 description 18
- 230000001629 suppression Effects 0.000 description 18
- 241000725303 Human immunodeficiency virus Species 0.000 description 16
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 13
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 13
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 13
- 206010037660 Pyrexia Diseases 0.000 description 13
- 101800001271 Surface protein Proteins 0.000 description 13
- 230000005856 abnormality Effects 0.000 description 13
- 208000037821 progressive disease Diseases 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 230000011664 signaling Effects 0.000 description 12
- 230000002411 adverse Effects 0.000 description 11
- 238000009175 antibody therapy Methods 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 11
- 206010016256 fatigue Diseases 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 238000002483 medication Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 230000000630 rising effect Effects 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 210000001280 germinal center Anatomy 0.000 description 10
- 230000002962 histologic effect Effects 0.000 description 10
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 229940053017 sylvant Drugs 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 206010067484 Adverse reaction Diseases 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 8
- 230000006838 adverse reaction Effects 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 206010029410 night sweats Diseases 0.000 description 8
- 230000036565 night sweats Effects 0.000 description 8
- 230000003285 pharmacodynamic effect Effects 0.000 description 8
- 238000009597 pregnancy test Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 231100000402 unacceptable toxicity Toxicity 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 229960001334 corticosteroids Drugs 0.000 description 7
- 230000007717 exclusion Effects 0.000 description 7
- 238000009533 lab test Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 230000003319 supportive effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 208000010201 Exanthema Diseases 0.000 description 6
- 206010020118 Histiocytoses Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- -1 immunoglobulin G Proteins 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010043554 thrombocytopenia Diseases 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 5
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 5
- 208000003623 Hypoalbuminemia Diseases 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000008771 Lymphadenopathy Diseases 0.000 description 5
- 208000031709 Skin Manifestations Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 208000022531 anorexia Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 5
- 229960001467 bortezomib Drugs 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- 206010018092 Generalised oedema Diseases 0.000 description 4
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 208000024783 anasarca Diseases 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 210000000285 follicular dendritic cell Anatomy 0.000 description 4
- 230000024924 glomerular filtration Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000003118 histopathologic effect Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 208000019420 lymphoid neoplasm Diseases 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 238000013188 needle biopsy Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 206010035485 plasmacytosis Diseases 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 201000006401 polyclonal hypergammaglobulinemia Diseases 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000000275 quality assurance Methods 0.000 description 4
- 208000037922 refractory disease Diseases 0.000 description 4
- 230000008085 renal dysfunction Effects 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000005751 tumor progression Effects 0.000 description 4
- OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 3
- 241000167854 Bourreria succulenta Species 0.000 description 3
- 208000034103 Castleman-Kojima disease Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 206010051792 Infusion related reaction Diseases 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 206010036105 Polyneuropathy Diseases 0.000 description 3
- 108010081750 Reticulin Proteins 0.000 description 3
- 208000012169 TAFRO syndrome Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 238000012550 audit Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000019693 cherries Nutrition 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229940124301 concurrent medication Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 238000013479 data entry Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000009093 first-line therapy Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 102000052986 human IL6ST Human genes 0.000 description 3
- OFNXOACBUMGOPC-UHFFFAOYSA-N hydroxystreptomycin Natural products CNC1C(O)C(O)C(CO)OC1OC1C(C=O)(O)C(CO)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O OFNXOACBUMGOPC-UHFFFAOYSA-N 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- OKPOKMCPHKVCPP-UHFFFAOYSA-N isoorientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(O)C=C3CCN2C)=C1 OKPOKMCPHKVCPP-UHFFFAOYSA-N 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000007824 polyneuropathy Effects 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- JTQHYPFKHZLTSH-UHFFFAOYSA-N reticulin Natural products COC1CC(OC2C(CO)OC(OC3C(O)CC(OC4C(C)OC(CC4OC)OC5CCC6(C)C7CCC8(C)C(CCC8(O)C7CC=C6C5)C(C)O)OC3C)C(O)C2OC)OC(C)C1O JTQHYPFKHZLTSH-UHFFFAOYSA-N 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000011594 Autoinflammatory disease Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010050685 Cytokine storm Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 description 2
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010025280 Lymphocytosis Diseases 0.000 description 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 2
- 206010028034 Mouth ulceration Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010053869 POEMS syndrome Diseases 0.000 description 2
- 208000002774 Paraproteinemias Diseases 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 208000006981 Skin Abnormalities Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000005485 Thrombocytosis Diseases 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000036981 active tuberculosis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 229960004238 anakinra Drugs 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 229950001565 clazakizumab Drugs 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 229950002507 elsilimomab Drugs 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 102000018511 hepcidin Human genes 0.000 description 2
- 108060003558 hepcidin Proteins 0.000 description 2
- 229940066919 hepcidin Drugs 0.000 description 2
- 208000021173 high grade B-cell lymphoma Diseases 0.000 description 2
- 206010066435 human herpesvirus 8 infection Diseases 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000011545 laboratory measurement Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000011475 lollipops Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 description 2
- 210000002346 musculoskeletal system Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 238000012148 non-surgical treatment Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 229950010006 olokizumab Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001373 regressive effect Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229950006348 sarilumab Drugs 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 229950006094 sirukumab Drugs 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000009528 vital sign measurement Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 1
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- AOYNUTHNTBLRMT-MXWOLSILSA-N 2-Deoxy-2(F-18)fluoro-2-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H]([18F])C=O AOYNUTHNTBLRMT-MXWOLSILSA-N 0.000 description 1
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000026326 Adult-onset Still disease Diseases 0.000 description 1
- LBYMZCVBOKYZNS-CIUDSAMLSA-N Ala-Leu-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O LBYMZCVBOKYZNS-CIUDSAMLSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 1
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000011546 CRP measurement Methods 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- JPAACTMBBBGAAR-HOTGVXAUSA-N Gly-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)CN)CC(C)C)C(O)=O)=CNC2=C1 JPAACTMBBBGAAR-HOTGVXAUSA-N 0.000 description 1
- FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 1
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 101000993443 Haemophilus influenzae Hemoglobin and hemoglobin-haptoglobin-binding protein A Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000018434 Iron-Regulatory Proteins Human genes 0.000 description 1
- 108010066420 Iron-Regulatory Proteins Proteins 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 244000303512 Peucedanum ostruthium Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- NQZFFLBPNDLTPO-DLOVCJGASA-N Ser-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)N NQZFFLBPNDLTPO-DLOVCJGASA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- YXGCIEUDOHILKR-IHRRRGAJSA-N Ser-Tyr-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N YXGCIEUDOHILKR-IHRRRGAJSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- 102100027662 Sphingosine kinase 2 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- UJGDFQRPYGJBEH-AAEUAGOBSA-N Trp-Ser-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N UJGDFQRPYGJBEH-AAEUAGOBSA-N 0.000 description 1
- VPEFOFYNHBWFNQ-UFYCRDLUSA-N Tyr-Pro-Tyr Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 VPEFOFYNHBWFNQ-UFYCRDLUSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000002718 aborted fetus Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 1
- GOHCTCOGYKAJLZ-UHFFFAOYSA-N ctep Chemical compound CC=1N(C=2C=CC(OC(F)(F)F)=CC=2)C(C)=NC=1C#CC1=CC=NC(Cl)=C1 GOHCTCOGYKAJLZ-UHFFFAOYSA-N 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000009553 follicular dendritic cell sarcoma Diseases 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 238000007386 incisional biopsy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010052987 latency-associated nuclear antigen Proteins 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 208000010949 lymph node disease Diseases 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229940005028 methylprednisolone 500 mg Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000011395 multi-agent chemotherapy Methods 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 206010057056 paraneoplastic pemphigus Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 229940060041 satralizumab Drugs 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000006000 skin carcinoma in situ Diseases 0.000 description 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 208000014754 thrombocytosis disease Diseases 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
L'invention concerne un anticorps ou un fragment de celui-ci pouvant inhiber l'IL-6 humaine pour une utilisation dans une méthode de traitement de la maladie de Castelman multicentrique idiopathique (iMCD) résistante chez un patient selon un schéma thérapeutique, le patient ayant préalablement été traité avec un schéma thérapeutique préalable et ayant eu une rechute ou ayant été réfractaire ou résistant au traitement avec le schéma thérapeutique antérieur; le schéma thérapeutique comprenant au moins un premier cycle de traitement d'intensité comprenant l'administration intraveineuse de l'anticorps dans une première densité de traitement par anticorps > 11 mg/kg par intervalle de trois semaines ou 11 mg/kg par intervalle < 3 semaines, ou le fragment à une densité de traitement de fragment équivalente ayant un effet antagoniste équivalent sur l'IL-6 humaine; et le schéma thérapeutique préalable comprenant l'administration intraveineuse d'un anticorps ou d'un fragment de celui-ci qui est un antagoniste de la voie de signalisation de l'IL-6 humaine, l'anticorps ou le fragment étant administré à une densité de traitement d'antagoniste de la voie de signalisation d'IL-6 qui est inférieure à la première densité de traitement d'anticorps ou à la densité de traitement de fragment équivalente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140078P | 2021-01-21 | 2021-01-21 | |
| US63/140,078 | 2021-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022157493A1 true WO2022157493A1 (fr) | 2022-07-28 |
Family
ID=80119462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2022/050151 WO2022157493A1 (fr) | 2021-01-21 | 2022-01-20 | Méthode de traitement de troubles histiocytaires et lymphoprolifératifs associés à il-6 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022157493A1 (fr) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
| WO2004039826A1 (fr) | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anticorps anti-il-6, compositions, methodes et utilisations associees |
| US10323095B2 (en) | 2014-03-17 | 2019-06-18 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
-
2022
- 2022-01-20 WO PCT/GB2022/050151 patent/WO2022157493A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
| WO2004039826A1 (fr) | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anticorps anti-il-6, compositions, methodes et utilisations associees |
| US10323095B2 (en) | 2014-03-17 | 2019-06-18 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
Non-Patent Citations (68)
| Title |
|---|
| "Common Terminology Criteria for Adverse Events (CTCAE", 27 November 2017, US DEPARTMENT OF HEALTH AND HUMAN SERVICES |
| "NCCN Clinical Practice Guidelines in Oncology", 22 January 2020, NATIONAL COMPREHENSIVE CANCER NETWORK |
| "Protocol CNT0328MCD2001", 20 June 2013, JANSSEN RESEARCH & DEVELOPMENT, article "A randomized, double-blind, placebo-controlled Phase 2 study to assess the efficacy and safety of CNTO 328 (anti-IL-6 monoclonal antibody) plus best supportive care compared with best supportive care in subjects with multicentric Castleman's disease" |
| "Siltuximab Investigator Brochure", June 2020 |
| "UniProt", Database accession no. P40189 |
| 0, JOOLODGE, MARTINWAHL, RICHARD: "Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0", RADIOLOGY, vol. 280, 2016, pages 142043 |
| ADEBANJO, O ET AL., J. CELL BIOLOGY, vol. 142, 1998, pages 1347 - 1356 |
| AGR. BIOL. CHEM., vol. 54, 1990, pages 2685 - 2688 |
| AKIYAMA MITSUHIRO ET AL: "Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab", ANNALS OF HEMATOLOGY, BERLIN, DE, vol. 96, no. 12, 1 September 2017 (2017-09-01), pages 2117 - 2119, XP036365460, ISSN: 0939-5555, [retrieved on 20170901], DOI: 10.1007/S00277-017-3111-X * |
| ANONYMOUS: "Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease (SISREMCAD)", 19 April 2021 (2021-04-19), pages 1 - 9, XP055903922, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04838860> [retrieved on 20220322] * |
| AOUBA A ET AL.: "Dramatic clinical efficacy of cladribine in Rosai-Dorfman disease and evolution of the cytokine profile: towards a new therapeutic approach", HAEMATOLOGICA, vol. 91, December 2006 (2006-12-01), pages ECR52 |
| AVVISTI, G ET AL., BAILLIERES CLINICAL HEMATOLOGY, vol. 8, 1995, pages 815 - 829 |
| BRIGHTON TAKHOT AHARRISON SJ. ET AL.: "Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma", CLIN CANCER, vol. 25, no. 13, 1 July 2019 (2019-07-01) |
| CHANDRASHEKARA S, INTERNET J RHEUMATOL AND CLIN IMMUNOL, vol. 2, no. S1, 2014, pages SR3 |
| CHESON B, FISHER R, BARRINGTON S: "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification", J CLIN ONCOL, vol. 32, 2014, pages 3059 - 3067 |
| CHESON BDHORNING SJCOIFFIER B ET AL.: "NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas", J CLIN ONCOL, vol. 17, no. 4, 1999, pages 1244 - 1253 |
| EMILE JF ET AL.: "Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages", BLOOD, vol. 127, no. 22, 2 June 2016 (2016-06-02), pages 2672 - 81, XP086506676, DOI: 10.1182/blood-2016-01-690636 |
| EMILIE D ET AL.: "Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients", BLOOD, vol. 80, 1992, pages 498 - 504 |
| EUR. J. BIOCHEM, vol. 168, 1987, pages 543 - 550 |
| FAJGENBAUM DC: "Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease", BLOOD, vol. 132, no. 22, 2018, pages 2323 - 2330 |
| FAJGENBAUM DCULDRICK TSBAGG A ET AL.: "International, evidence-based consensus diagnostic criteria for HHV-8- negative/idiopathic multicentric Castleman disease", BLOOD, vol. 129, no. 12, 23 March 2017 (2017-03-23), pages 1646 - 1657, XP086677020, Retrieved from the Internet <URL:https:l/www.ncbi.nlm,nih,oov/pubmed/28087540> DOI: 10.1182/blood-2016-10-746933 |
| FAJGENBAUM DCULDRICK TSBAGG A ET AL.: "International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease", BLOOD, vol. 129, no. 12, 2017, pages 1646 - 1657, XP086677020, DOI: 10.1182/blood-2016-10-746933 |
| FAJGENBAUM DCULDRICK TSBAGG A ET AL.: "International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease", BLOOD, vol. 192, no. 12, 23 March 2017 (2017-03-23), pages 1646 - 1657, XP086677020, Retrieved from the Internet <URL:https://www.ncbi.nim.nih.qov/oubmed/28087540> DOI: 10.1182/blood-2016-10-746933 |
| FDACENTER FOR DRUG EVALUATION AND RESEARCH, GUIDANCE FOR INDUSTRY ESTIMATING THE MAXIMUM SAFE STARTING DOSE IN INITIAL CLINICAL TRIALS FOR THERAPEUTICS IN ADULT HEALTHY, Retrieved from the Internet <URL:http://www.fda.qov/cder/quidance/index.htm> |
| FRITS VAN RHEE ET AL: "A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease", ONCOTARGET, vol. 6, no. 30, 3 August 2015 (2015-08-03), XP055441655, DOI: 10.18632/oncotarget.4655 * |
| FULCINITI, M.HIDESHIMA, T.VERMOT-DESROCHES, C.POZZI, S.NANJAPPA, P.SHEN, Z.TAI, Y. T.: "A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma", CLINICAL CANCER RESEARCH, vol. 15, no. 23, 2009, pages 7144 - 7152, XP055045972, DOI: 10.1158/1078-0432.CCR-09-1483 |
| GARBERS CHEINK SKORN TROSE-JOHN S: "Interleukin-6: designing specific therapeutics for a complex cytokine", NAT REV DRUG DISCOV, vol. 17, no. 6, June 2018 (2018-06-01), pages 395 - 412, XP055753837, DOI: 10.1038/nrd.2018.45 |
| GRITTI GRAIMONDI FRIPAMONTI D ET AL.: "Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support", MEDRXIV, 2020 |
| HEINRICH PCCASTELL JVANDUS T: "Interleukin-6 and the acute phase response", BIOCHEM J, vol. 265, no. 3, 1990, pages 621 - 636 |
| IGAWA TSATO Y: "TAFRO Syndrome", HEMATOL ONCOL CLIN NORTH AM, vol. 32, no. 1, February 2018 (2018-02-01), pages 107 - 118 |
| ISHIMI, Y ET AL., J. IMMUNOLOGY, vol. 145, 1990, pages 3297 - 3303 |
| J. IMMUNOL., vol. 140, 1988, pages 1534 - 1541 |
| JANSSEN, MF, BONSEL, GJ, LUO, N: "Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries", PHARMACOECONOMICS, vol. 36, 2018, pages 675 - 697, Retrieved from the Internet <URL:https://doi.oro/10.1007/s40273-018-0623-8> |
| JUSTIZ VAILLANT AASTANG CM: "StatPearls", January 2020, STATPEARLS PUBLISHING, article "Lymphoproliferative Disorders" |
| KLEIN BZHANG XLU ZBATAILLE R: "Interleukin-6 in human multiple myeloma", BLOOD, vol. 85, 1995, pages 863 - 872 |
| KURZROCK RVOORHEES PMCASPER C ET AL.: "A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease", CLIN CANCER RES, vol. 19, no. 13, 1 July 2013 (2013-07-01), pages 3659 - 70 |
| LANCET ONCOL, vol. 15, no. 10, September 2014 (2014-09-01), pages 417 |
| LEE, E.LIANG, Q.ALI, H. ET AL.: "Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery", NAT BIOTECHNOL, vol. 32, 2014, pages 356 - 363, XP037135270, Retrieved from the Internet <URL:https://doi.org/10.1038/nbt.2825> DOI: 10.1038/nbt.2825 |
| MARSH RA: "Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis", FRONT IMMUNOL, vol. 8, 2018, pages 1902 |
| MATSUDA, T ET AL., EUR. J. IMMUNOL., vol. 18, 1988, pages 951 - 956 |
| MAYER CHRISTINA L ET AL: "Dose selection of siltuximab for multicentric Castleman's dis", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG , BERLIN, DE, vol. 75, no. 5, 18 March 2015 (2015-03-18), pages 1037 - 1045, XP035497616, ISSN: 0344-5704, [retrieved on 20150318], DOI: 10.1007/S00280-015-2720-0 * |
| MAYER CLXIE LBANDEKAR R ET AL.: "Dose selection of siltuximab for multicentric Castleman's disease", CANCER CHEMOTHER PHARMACOL, vol. 75, no. 5, May 2015 (2015-05-01), pages 1037 - 45, XP035497616, DOI: 10.1007/s00280-015-2720-0 |
| MEASE PJGOTTLIEB AB ET AL.: "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis", ARTHRITIS RHEUMATOL, vol. 68, no. 9, September 2016 (2016-09-01), pages 2163 - 73, XP055846705, DOI: 10.1002/art.39700 |
| MORRA DEPIERSON SK ET AL.: "Predictors of response to anti-IL-6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data", BR J HAEMATOL., vol. 184, no. 2, January 2019 (2019-01-01), pages 232 - 241, XP071162948, DOI: 10.1111/bjh.15588 |
| MORRA DEPIERSON SKSHILLING D ET AL.: "Predictors of response to anti-IL-6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data", BR J HAEMATOL, vol. 184, no. 2, January 2019 (2019-01-01), pages 232 - 241, XP071162948, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15588> DOI: 10.1111/bjh.15588 |
| NEMETH ERIVERA SGABAYAN V ET AL.: "IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin", J. CLIN. INVEST., vol. 113, 2004, pages 1271 - 1276, XP055619212 |
| NEUBERGER ET AL., 8TH INTERNATIONAL BIOTECHNOLOGY SYMPOSIUM, 1998, pages 792 - 799 |
| NIKANJAM MYANG JCAPPARELLI EV: "Population pharmacokinetics of siltuximab: impact of disease state", CANCER CHEMOTHER PHARMACOL., vol. 84, no. 5, 2019, pages 993 - 1001, XP036906636, DOI: 10.1007/s00280-019-03939-7 |
| OKEN MMCREECH RHTORMEY DC ET AL.: "Toxicity and response criteria of the Eastern Cooperative Oncology Group", AM J CLIN ONCOL, vol. 5, no. 6, 1982, pages 649 - 655 |
| ORLOWSKI RZGERCHEVA LWILLIAMS C. ET AL.: "A phase II, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma", AM J HEMATOL, vol. 90, no. 1, January 2015 (2015-01-01), pages 42 - 49 |
| POLI, V. ET AL., EMBO, vol. 13, 1994, pages 1189 - 1196 |
| PUCHALSKI TPRABHAKAR UJIAO QBERNS BDAVIS HM: "Pharmacokinetic and pharmacodynamic modeling of an antiinterleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma", CLIN CANCER RES, vol. 16, no. 5, 2010, pages 1652 - 1661 |
| SATO, K ET AL., THE ABSTRACTS OF THE 21ST ANNUAL MEETING OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 21, 1991, pages 166 |
| SHAH JJFENG LTHOMAS SK ET AL.: "Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly diagnosed, previously untreated multiple myeloma: an open- label phase I trial", BLOOD CANCER JOURNAL, vol. 6, 2016, pages e396 |
| SHAW, S.BOURNE, T.MEIER, C.CARRINGTON, B.GELINAS, R.HENRY, A. ET AL.: "Discovery and characterization of olokizumab", MABS, vol. 6, no. 3, 2014, pages 773 - 781 |
| SMOLEN JSWEINBLATT MESHENG SZHUANG YHSU B: "Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy", ANN RHEUM DIS, vol. 73, no. 9, 3 April 2014 (2014-04-03), pages 1616 - 25, XP055644870, DOI: 10.1136/annrheumdis-2013-205137 |
| STERN ROBERT M. ET AL: "Targeting the mTOR pathway in idiopathic multicentric Castleman disease", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 129, no. 10, 1 October 2019 (2019-10-01), GB, pages 4086 - 4088, XP055903999, ISSN: 0021-9738, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763220/pdf/jci-129-131332.pdf> DOI: 10.1172/JCI131332 * |
| SWERDLOW SH ET AL.: "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", BLOOD, vol. 127, no. 20, 19 May 2016 (2016-05-19), pages 2375 - 90 |
| TONIALINI L ET AL: "Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program", HEMATOLOGICAL ONCOLOGY, vol. 36, no. 4, 3 August 2018 (2018-08-03), pages 689 - 692, XP055903942, DOI: .10.1002/hon.2532 * |
| TONIALINI LBONFICHI MFERRERO S ET AL.: "Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program", HEMATOLOGICAL ONCOLOGY, vol. 36, 2018, pages 689 - 692 |
| VAN RHEE F ET AL.: "Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial", LANCET ONCOL, vol. 15, no. 9, 17 July 2014 (2014-07-17), pages 966 - 74, XP055747111, DOI: 10.1016/S1470-2045(14)70319-5 |
| VAN RHEE F, ROTHMAN M, HO KF: "Patient-reported outcomes for multicentric Castleman's disease in a randomized, placebo-controlled study of siltuximab", PATIENT, vol. 8, no. 2, April 2015 (2015-04-01), pages 207 - 16, XP055643715, Retrieved from the Internet <URL:https://www.ncbi.nim.nih.gov/pubmed/25736164> DOI: 10.1007/s40271-015-0120-5 |
| VAN RHEE FFAYAD LVOORHEES P ET AL.: "Siltuximab, a novel anti-interleukin-6 monoclonal antibody for Castleman disease", J CLIN ONCOL, vol. 28, no. 23, 2010, pages 3701 - 3708, XP055254538, DOI: 10.1200/JCO.2009.27.2377 |
| VAN RHEE FRITS ET AL: "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease", BLOOD, vol. 132, no. 20, 15 November 2018 (2018-11-15), US, pages 2115 - 2124, XP055904003, ISSN: 0006-4971, Retrieved from the Internet <URL:https://watermark.silverchair.com/blood862334.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA-UwggPhBgkqhkiG9w0BBwagggPSMIIDzgIBADCCA8cGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMCMYrzJdCh_otyOO4AgEQgIIDmNAWVKJSbrsuF15lqr96fP6bqvHGPS2R6iI3jVuWSOCKcYRqDk6iFB4fMJXLO0bgymve03qHQMtCZHDG14vaZ8qw> DOI: 10.1182/blood-2018-07-862334 * |
| VAN RHEE FVOORHEES P ET AL.: "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease", BLOOD, vol. 132, no. 20, 2018, pages 2115 - 2124 |
| VAN RHEE FVOORHEES PDISPENZIERI A ET AL.: "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease", BLOOD, vol. 132, no. 20, 15 November 2018 (2018-11-15), pages 2115 - 2124 |
| VAN RHEE FWONG RSMUNSHI N ET AL.: "Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial", LANCET ONCOL, vol. 15, no. 9, August 2014 (2014-08-01), pages 966 - 74, XP055747111, DOI: 10.1016/S1470-2045(14)70319-5 |
| WIJDENES JCLEMENT CKLEIN B ET AL.: "Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies", MOL IMMUNOL, vol. 28, no. 11, 1991, pages 1183 - 1192, XP023852664, DOI: 10.1016/0161-5890(91)90004-4 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6250109B2 (ja) | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 | |
| RU2726996C1 (ru) | Применение ингибиторов иммунных контрольных точек при новообразованиях центральной нервной системы | |
| US8398972B2 (en) | Methods of treating dementia using a GM-CSF antagonist | |
| US20180237532A1 (en) | Method for the treatment of multiple sclerosis | |
| JP2022064930A (ja) | インテグリンベータ７アンタゴニスト及びクローン病の治療方法 | |
| JP2017078075A (ja) | 対象の選択および治療 | |
| US20230364254A1 (en) | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| CN112839956A (zh) | 安全有效治疗膝和/或髋疼痛的药物组合物 | |
| WO2022157493A1 (fr) | Méthode de traitement de troubles histiocytaires et lymphoprolifératifs associés à il-6 | |
| US20230330251A1 (en) | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| US20110104153A1 (en) | Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients | |
| WO2010093814A1 (fr) | Procédés de traitement de la démence en utilisant un antagoniste de gm-csf | |
| WO2022162351A1 (fr) | Méthodes de traitement de troubles rares au moyen d'une thérapie anti-il-6 | |
| US20230235069A1 (en) | Treatment of atopic dermatitis | |
| US20230340110A1 (en) | Dosages | |
| WO2022097090A1 (fr) | Schéma posologique et polythérapies avec des anticorps multispécifiques ciblant un antigène de maturation des lymphocytes b et des inhibiteurs de gamma secrétase | |
| WO2022162357A1 (fr) | Méthodes de traitement d'une maladie liée à l'igg4 par une thérapie anti-il-6 | |
| WO2022162352A1 (fr) | Méthodes de traitement de troubles rares au moyen d'une thérapie anti-il-6 | |
| WO2022162358A1 (fr) | Méthodes de traitement de troubles rares au moyen d'une thérapie anti-il-6 | |
| JP2023537751A (ja) | オクレリズマブで多発性硬化症を治療するための方法 | |
| JP2024511078A (ja) | 抗ｉｌ－１３抗体を用いてアトピー性皮膚炎を処置する方法 | |
| WO2022162354A1 (fr) | Méthodes de traitement de troubles rares au moyen d'une thérapie anti-il-6 | |
| TW202330613A (zh) | 使用整聯蛋白β７拮抗劑治療克隆氏病之方法 | |
| CN108473576A (zh) | 用于治疗复发形式的多发性硬化的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22702017 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22702017 Country of ref document: EP Kind code of ref document: A1 |